Literature DB >> 22345513

Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors.

Gregory J Gores1, Scott H Kaufmann.   

Abstract

Bcl-2, Bcl-x(L), Mcl-1, and A1 are the predominant anti-apoptotic members of the Bcl-2 family in somatic cells. Malignant B lymphocytes are critically dependent on Bcl-2 or Bcl-x(L) for survival. In contrast, a new study by Glaser and colleagues in the January 15, 2012, issue of Genes & Development (pp. 120-125) demonstrates that Mcl-1 is essential for development and survival of acute myelogenous leukemia cells. These results provide new impetus for the generation of selective Mcl-1 inhibitors.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22345513      PMCID： PMC3289878          DOI： 10.1101/gad.186189.111

Source DB:  PubMed          Journal:  Genes Dev        ISSN： 0890-9369            Impact factor:   11.361


  46 in total

Review 1.  Life and death during hematopoietic differentiation.

Authors:  Joseph T Opferman
Journal:  Curr Opin Immunol       Date:  2007-07-26       Impact factor: 7.486

2.  To trigger apoptosis, Bak exposes its BH3 domain and homodimerizes via BH3:groove interactions.

Authors:  Grant Dewson; Tobias Kratina; Huiyan W Sim; Hamsa Puthalakath; Jerry M Adams; Peter M Colman; Ruth M Kluck
Journal:  Mol Cell       Date:  2008-05-09       Impact factor: 17.970

3.  Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Authors:  Farhad Ravandi; Jorge E Cortes; Daniel Jones; Stefan Faderl; Guillermo Garcia-Manero; Marina Y Konopleva; Susan O'Brien; Zeev Estrov; Gautam Borthakur; Deborah Thomas; Sherry R Pierce; Mark Brandt; Anna Byrd; B Nebiyou Bekele; Keith Pratz; Rajyalakshmi Luthra; Mark Levis; Michael Andreeff; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

4.  Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival.

Authors:  Martin Schwickart; Xiaodong Huang; Jennie R Lill; Jinfeng Liu; Ronald Ferrando; Dorothy M French; Heather Maecker; Karen O'Rourke; Fernando Bazan; Jeffrey Eastham-Anderson; Peng Yue; David Dornan; David C S Huang; Vishva M Dixit
Journal:  Nature       Date:  2009-12-20       Impact factor: 49.962

5.  mir-29 regulates Mcl-1 protein expression and apoptosis.

Authors:  J L Mott; S Kobayashi; S F Bronk; G J Gores
Journal:  Oncogene       Date:  2007-04-02       Impact factor: 9.867

6.  mTORC1 promotes survival through translational control of Mcl-1.

Authors:  John R Mills; Yoshitaka Hippo; Francis Robert; Samuel M H Chen; Abba Malina; Chen-Ju Lin; Ulrike Trojahn; Hans-Guido Wendel; Al Charest; Roderick T Bronson; Scott C Kogan; Robert Nadon; David E Housman; Scott W Lowe; Jerry Pelletier
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-29       Impact factor: 11.205

Review 7.  Unique biology of Mcl-1: therapeutic opportunities in cancer.

Authors:  Matthew R Warr; Gordon C Shore
Journal:  Curr Mol Med       Date:  2008-03       Impact factor: 2.222

8.  MicroRNA 29b functions in acute myeloid leukemia.

Authors:  Ramiro Garzon; Catherine E A Heaphy; Violaine Havelange; Muller Fabbri; Stefano Volinia; Twee Tsao; Nicola Zanesi; Steven M Kornblau; Guido Marcucci; George A Calin; Michael Andreeff; Carlo M Croce
Journal:  Blood       Date:  2009-10-22       Impact factor: 22.113

Review 9.  MLL fusions: pathways to leukemia.

Authors:  Han Liu; Emily H Y Cheng; James J D Hsieh
Journal:  Cancer Biol Ther       Date:  2009-07       Impact factor: 4.742

10.  The landscape of somatic copy-number alteration across human cancers.

Authors:  Rameen Beroukhim; Craig H Mermel; Dale Porter; Guo Wei; Soumya Raychaudhuri; Jerry Donovan; Jordi Barretina; Jesse S Boehm; Jennifer Dobson; Mitsuyoshi Urashima; Kevin T Mc Henry; Reid M Pinchback; Azra H Ligon; Yoon-Jae Cho; Leila Haery; Heidi Greulich; Michael Reich; Wendy Winckler; Michael S Lawrence; Barbara A Weir; Kumiko E Tanaka; Derek Y Chiang; Adam J Bass; Alice Loo; Carter Hoffman; John Prensner; Ted Liefeld; Qing Gao; Derek Yecies; Sabina Signoretti; Elizabeth Maher; Frederic J Kaye; Hidefumi Sasaki; Joel E Tepper; Jonathan A Fletcher; Josep Tabernero; José Baselga; Ming-Sound Tsao; Francesca Demichelis; Mark A Rubin; Pasi A Janne; Mark J Daly; Carmelo Nucera; Ross L Levine; Benjamin L Ebert; Stacey Gabriel; Anil K Rustgi; Cristina R Antonescu; Marc Ladanyi; Anthony Letai; Levi A Garraway; Massimo Loda; David G Beer; Lawrence D True; Aikou Okamoto; Scott L Pomeroy; Samuel Singer; Todd R Golub; Eric S Lander; Gad Getz; William R Sellers; Matthew Meyerson
Journal:  Nature       Date:  2010-02-18       Impact factor: 49.962
View more
  47 in total

1.  Inhibitors of the Antiapoptotic Myeloid Cell Leukemia-1 (Mcl-1) May Provide Effective Treatment for Cancer.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2015-11-30       Impact factor: 4.345

Review 2.  Pathways and mechanisms of venetoclax resistance.

Authors:  Prithviraj Bose; Varsha Gandhi; Marina Konopleva
Journal:  Leuk Lymphoma       Date:  2017-01-31

Review 3.  Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy.

Authors:  Peter E Czabotar; Guillaume Lessene; Andreas Strasser; Jerry M Adams
Journal:  Nat Rev Mol Cell Biol       Date:  2014-01       Impact factor: 94.444

4.  Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma.

Authors:  Ayano Kabashima; Petra Hirsova; Steven F Bronk; Matthew C Hernandez; Mark J Truty; Sumera Rizvi; Scott H Kaufmann; Gregory J Gores
Journal:  J Hepatol       Date:  2018-03-09       Impact factor: 25.083

5.  Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.

Authors:  Rongqing Pan; Vivian R Ruvolo; Jun Wei; Marina Konopleva; John C Reed; Maurizio Pellecchia; Michael Andreeff; Peter P Ruvolo
Journal:  Blood       Date:  2015-06-04       Impact factor: 22.113

6.  Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.

Authors:  Xiaojia Niu; Jianyun Zhao; Jun Ma; Chengzhi Xie; Holly Edwards; Guan Wang; J Timothy Caldwell; Shengyan Xiang; Xiaohong Zhang; Roland Chu; Zhihong J Wang; Hai Lin; Jeffrey W Taub; Yubin Ge
Journal:  Clin Cancer Res       Date:  2016-04-21       Impact factor: 12.531

7.  Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression.

Authors:  Kenichiro Doi; Qiang Liu; Krishne Gowda; Brian M Barth; David Claxton; Shantu Amin; Thomas P Loughran; Hong-Gang Wang
Journal:  Cancer Biol Ther       Date:  2014-05-19       Impact factor: 4.742

Review 8.  The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia.

Authors:  Su-Fern Tan; Jennifer M Pearson; David J Feith; Thomas P Loughran
Journal:  Expert Opin Ther Targets       Date:  2017-05-02       Impact factor: 6.902

9.  Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma.

Authors:  Joachim C Mertens; Christian D Fingas; John D Christensen; Rory L Smoot; Steven F Bronk; Nathan W Werneburg; Michael P Gustafson; Allan B Dietz; Lewis R Roberts; Alphonse E Sirica; Gregory J Gores
Journal:  Cancer Res       Date:  2012-12-05       Impact factor: 12.701

10.  13-Oxyingenol dodecanoate, a cytotoxic ingenol derivative, induces mitochondrial apoptosis and caspase-dependent Akt decrease in K562 cells.

Authors:  Ming Liu; Weiyi Zhang; Genzhu Wang; Xiaoping Song; Xingzeng Zhao; Xiangyun Wang; Xin Qi; Jing Li
Journal:  Tumour Biol       Date:  2015-11-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.